Skip to main content
Fig. 7 | The Journal of Headache and Pain

Fig. 7

From: Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders

Fig. 7

Galcanezumab effects on incidence of headache after occurrence of premonitory symptoms in super-responders and super non-responders. A Incidence of all premonitory symptoms that were followed by headache decrease nearly fourfold more in the super-responders than the super non-responders. Note that after occurrence of premonitory symptoms, super-responders experienced significantly less headaches than super non-responders (p = 0.001, DF = 1, Fisher exact). B Incidences of headache following occurrence of each of the 9 most common premonitory symptoms during the 3-month treatment period. Note that in the super non-responder group galcanezumab treatment did not reduce incidence of headache after occurrence of 7/9 premonitory symptoms

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us